AMLX

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Cambridge, Massachusetts. The company went public in January 2022 and initially gained prominence with its ALS drug RELYVRIO, which received FDA approval in September 2022. However, following disappointing Phase 3 trial results, Amylyx voluntarily withdrew RELYVRIO from the market in April 2024. The company has since pivoted to focus on developing treatments for rare neurodegenerative and endocrine disorders, with its lead asset avexitide targeting post-bariatric hypoglycemia.